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http://www.biomedcentral.com/1471-5945/12/10RESEARCH ARTICLE Open AccessBudget impact analysis of ustekinumab in the
management of moderate to severe psoriasis
in Greece
Georgia Avgerinou3†, Ioannis Bassukas1†, Georgios Chaidemenos2†, Andreas Katsampas3†, Marita Kosmadaki3†,
Hara Kousoulakou8*, Athanasios Petridis1†, Brad Schenkel9, Dimitrios Sotiriadis4†, Theofanis Spiliopoulos5†,
Panagiotis Stavropoulos3†, Evgenia Toumpi6† and Loukas Xaplanteris7Abstract
Background: The purpose of this study was to estimate the annual and per-patient budget impact of the
treatment of moderate to severe psoriasis in Greece before and after the introduction of ustekinumab.
Methods: A budget impact model was constructed from a national health system perspective to depict the clinical
and economic aspects of psoriasis treatment over 5 years. The model included drug acquisition, monitoring, and
administration costs for both the induction and maintenance years for patients in a treatment mix with etanercept,
adalimumab, infliximab, with or without ustekinumab. It also considered the resource utilization for non-responders.
Greek treatment patterns and resource utilization data were derived from 110 interviews with dermatologists
conducted in February 2009 and evaluated by an expert panel of 18 key opinion leaders. Officially published
sources were used to derive the unit costs. Costs of adverse events and indirect costs were excluded from the
analysis. Treatment response was defined as the probability of achieving a PASI 50, PASI 75, or PASI 90 response,
based on published clinical trial data.
Results: The inclusion of ustekinumab in the biological treatment mix for moderate to severe psoriasis is predicted to
lead to total per-patient savings of €443 and €900 in years 1 and 5 of its introduction, respectively. The cost savings
were attributed to reduced administration costs, reduced hospitalizations for non-responders, and improved efficacy.
These results were mainly driven by the low number of administrations required with ustekinumab over a 5 year
treatment period (22 for ustekinumab, compared with 272 for etanercept, 131 for adalimumab, and 36 for infliximab).
Conclusions: The inclusion of ustekinumab in the treatment of moderate to severe psoriasis in Greece is anticipated to
have short- and long-term health and economic benefits, both on an annual and per-patient basis.Background
Psoriasis is a chronic, currently incurable, inflammatory
skin disease. It is characterized by relapses and remis-
sions, and is affected by several genetic and environmen-
tal factors [1]. Estimates of the worldwide prevalence of
psoriasis range from 0.5% to 4.6% [2], with males and
females being equally affected [1]. In Greece, the relative
prevalence of psoriasis is 2.8% based on an 8-year
prevalence study in an outpatient setting of a general* Correspondence: hkousoulakou@prmaconsulting.com
†Equal contributors
8PRMA Consulting Ltd, Hampshire, UK
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distribution, and reproduction in any mediumstate hospital dermatological teaching clinic [3]. Ethnic
variations have been identified and Caucasians are more
likely to suffer from the disease. The median age of
onset is 28 years [2].
The most common type of psoriasis, occurring in
more than 80% of cases, is plaque psoriasis or psoriasis
vulgaris, characterized by well-demarcated erythematous
scaly plaques [4]. Thirty-five percent of those with
plaque psoriasis suffer from moderate to severe disease
[5], which is usually defined as psoriasis affecting at least
10% of body surface area or a Psoriasis Area and Sever-
ity Index (PASI) score of 10 or more [1].
The chronic and incurable nature of plaque psoriasis
indicates that it has a major social and economic impacttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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psoriasis can be profound. The extent to which psoriasis
affects a person’s health-related quality of life (HRQoL)
is similar to that of other chronic diseases, such as arth-
ritis, chronic lung disease, and type 2 diabetes [7]. Those
with more severe psoriasis experience similar levels of
anxiety to patients with conditions such as breast cancer,
osteoporosis, or metastatic prostate cancer [8,9]. In a US
study of 265 adults with psoriasis, 32% screened positive
for depression and there was a graded relationship be-
tween depressive symptoms and HRQoL impairment
(P< 0.001). More than 16% of those with high depression
scores were treated with antidepressant medication. Both
dissatisfaction with psoriasis treatment and illness-
related stress were highly associated with depression
[10]. Many people with psoriasis report moderate to
severe feelings of stigmatization, anxiety, anger, and
depression [11]. Increasing severity of psoriasis is
closely correlated with suicidal ideation [12,13].
The annual, per-patient direct cost of psoriasis has
been reported to be more than $14,600 in the US [14],
£3,800 in the UK [15], and more than €5,000 in Italy
[16]. The economic burden of psoriasis has not yet been
evaluated in Greece.
One of the goals of psoriasis therapy is to reduce or
clear plaques and induce remission [17]. The ideal ther-
apy is an efficacious, long-lasting agent that is devoid of
acute or long-term adverse effects, with minimal moni-
toring requirements and a dosing regimen that facilitates
adherence [17]. These characteristics may help to reduce
treatment costs while maintaining improvements in
patients’ HRQoL [18,19].
Currently available systemic treatments for moderate
to severe psoriasis include conventional drug therapies
(cyclosporine, methotrexate, retinoids, and photother-
apy) and biologics. The former have demonstrated vary-
ing degrees of efficacy, and long-term use can lead to
serious side-effects [17]. In addition, systemic therapies
lack durable efficacy (the symptoms of psoriasis recur
shortly after withdrawal of conventional therapies) and
have inconvenient administration schedules (e.g., daily
dosing, multiple weekly exposures) [17].
On the other hand, the available biologic agents
(infliximab, etanercept, adalimumab, and ustekinumab)
provide specific, targeted regulation of the cells in the
immune system and pathophysiologically designed inter-
vention in the immunological disease cascade of psoria-
sis. They thus offer a treatment choice for patients who
have moderate to severe disease where “conventional”
systemic treatments have failed, are contraindicated, or
not tolerated [20].
The primary safety concern with biologic agents is im-
munosuppression. Biologic agents are associated with
increased risk of infection, serious infection and possiblymalignancies [21]. The safety of biologic agents com-
pared with conventional therapies for the treatment of
psoriasis has not yet been precisely defined [22].
Ustekinumab is the most recent biologic agent to
come to market. It was approved in Europe in January
2009 and has been shown to be well tolerated, to im-
prove moderate to severe psoriasis, and to have a favor-
able administration and monitoring schedule (one
subcutaneous injection every 12 weeks during the main-
tenance period) [23,24]. Moreover, in the Phase 3 rando-
mized clinical trials, the PASI 75 results achieved with
ustekinumab were sustained through at least 52 weeks
[25,26].
The objective of this study was to estimate the annual
and per-patient budget impact of the introduction of
ustekinumab as a treatment alternative for patients with
moderate to severe psoriasis in Greece, and to test the
hypothesis that a treatment with improved risk–benefit
and administration profiles compared with existing
treatments can lead to cost savings.
Methods
An economic model that estimated the annual and per-
patient budget impact of ustekinumab was built in Excel
2007. The budget impact model estimated the impact of
introducing ustekinumab into the treatment mix of bio-
logic agents available for the treatment of moderate to
severe plaque psoriasis in Greece, by comparing the
costs incurred by the national health system before and
after the introduction of ustekinumab.
All available biologic agents for the treatment of mod-
erate to severe psoriasis in Greece, namely ustekinumab,
etanercept, infliximab, and adalimumab, were included
in the model as treatment options. Efalizumab was
excluded from the analysis as its European marketing
authorization was suspended in February 2009.
Model structure
The economic analysis was performed from a national
health system perspective. The model time frame was
5 years (base year 2009), during which the prevalence of
psoriasis was assumed to be constant. The treatment re-
sponse to biologic therapies was measured in terms of
the probability of achieving a PASI 75 response, and the
annual costs and resource utilization of both responders
and non-responders to biologic treatment were consid-
ered in the model.
Model inputs
Clinical data
Data on the clinical efficacy of biologic agents were taken
from the meta-analysis conducted by Reich and collea-
gues [27]. This systematic literature review included all
randomized controlled trials (until October 2008) that
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ment of moderate to severe psoriasis. A total of 20 studies
enrolling 10,108 patients with psoriasis were included in
the meta-analysis, including three Phase 3 trials of usteki-
numab (PHOENIX 1, PHOENIX 2, and ACCEPT trials
[25,26,28]). The estimated mean PASI 75 response rates
per product are presented in Table 1.
Resource utilization data
Data on medical resource use were collected through
face-to-face interviews with dermatologists, the results
of which were validated by an expert panel of 18
dermatologists.
The interviews were undertaken during January–
March 2009 and included two stages. The first stage
involved 5 minutes of computer-assisted telephone inter-
views (CATI), which aimed to identify dermatologists
who were eligible for the second stage of the survey.
CATI participants were randomly selected through a
database including contact details for all registered
members of the Hellenic Society of Dermatology and
Venereology, which is publicly available on the official
website of the society (http://www.edae.gr/). Random-
ization was based on market research techniques and
resulted in a total of 200 dermatologists, who were
both office and hospital based, and were from Athens,
Thessaloniki (Salonica), and other urban centers.
Following CATI, a sample of 110 dermatologists was
selected for the second stage of the primary research,
based on specific quotas, the most important of which
were the number of patients with psoriasis treated by
each physician and the number of psoriasis patients for
the treatment of whom the physician was personally re-
sponsible. The reason behind that was to include in the
survey experienced dermatologists, actively involved in
the treatment of psoriasis. The second stage included
30-minute face-to-face interviews with the 110 derma-
tologists, the characteristics of whom are presented in
Table 2.
A 40-item questionnaire (both quantitative and quali-
tative) was developed with the aim of exploring: a) epi-
demiologic data (number of patients with plaque
psoriasis, percentage of patients with moderate to severeTable 1 Mean percentage of patients achieving PASI 75
response with psoriasis biologic treatments





aThe relevant dosing scheme for each product is presented in Table 3.
CI, confidence interval; PASI, Psoriasis Area and Severity Index.
Source: Reich et al., 2012.disease); b) treatment pathways (percentage of patients
receiving pharmaceutical treatment, percentage receiving
monotherapy versus combined treatment, percentage re-
ceiving biologic agents versus conventional systemic
therapy); and c) resource utilization of both responders
and non-responders (frequency and setting of adminis-
tration, number of annual outpatient visits to physicians’
offices and hospitals, duration of hospitalizations) (see
Additional file 1: Primary research questionnaire). Non-
responders were defined as patients who did not achieve
a PASI 75 response.
The interviews were based on a retrospective analysis
on the use of biologic agents and on a hypothetical pro-
jection regarding the use of ustekinumab. In particular,
the dermatologists were asked to consider their work-
load over the last month and provide information on
moderate to severe psoriasis epidemiology and resource
utilization based on their own experiences. The aim was
to gather information on usual practice as opposed to
best practice, as the former is more informative for de-
termining the actual costs of treatment.
All data collected in the interviews were validated by
an expert panel of 18 key opinion leaders in dermatol-
ogy, who were selected on the basis of being either dis-
tinguished academics or managers of psoriasis treatment
centers. The experts included in the panel represented
all major geographic regions of Greece. No Ethics Com-
mittee approval was requested for the primary research
component of the study, as the conduct of interviews
with physicians and Experts' Panel are not subject to any
approval according to the Greek legislation.
The questionnaire used during the expert panel pro-
cedure was the same as that used in the interviews. The
findings from the original interviews were projected on a
screen and the expert panel was asked to either confirm
or reject them using a tele-voting system. If more than
60% of the experts disagreed with the findings of the
fieldwork, they were invited to answer the same question
based on their experience. The average of the experts’
answers was then included in the model. The experts’
opinions were also used to inform the model on the
market shares of the biologic agents, with and without
ustekinumab.Table 2 Distribution of the 110 interviewed
dermatologists by place of work and area
Place of work Number of dermatologists %
Office based 70 64




Other urban centers 20 18
Table 3 Dosing scheme per product used in the analysis
Agent Dosing scheme
Adalimumab 80 mg at week 0, 40 mg at week 1,
then 40 mg every other week
Etanercept 50 mg twice weekly for 12 weeks,
then 50 mg once weekly
Infliximab 5 mg/kg at weeks 0, 2, and 6,
then every 8 weeks
Ustekinumab 45 mg at weeks 0 and 4,
then every 12 weeks
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Economic evaluations should go beyond the acquisition
cost of drugs in order to reflect real-life clinical practice.
Costing in this way requires that all resources used by a
particular program or treatment are identified and valued.
To health economists, cost refers to the sacrifice of
benefits made when a given resource is consumed in a
program or treatment – in other words, the opportunity
cost. The value of opportunity forgone in the next-best
alternative use of health resources does not necessarily
equate to the market price of the resources used, be-
cause the total costs of treatment should be considered.
The total costs comprise the sum of all expenditures
during a given time frame, including the direct costs in-
curred by the health care provider and patient, as well as
the indirect costs to society of productivity lost. It is im-
portant to assess the relative importance of a cost item
to the overall outcome, since the inclusion of minor
costs may not be justified in certain cases. An example is
when the cost of drug acquisition (a direct cost) far out-
weighs the magnitude of other costs, such as productiv-
ity loss (an indirect cost). Thus, in this model, only
direct costs expressed in euros (2009) were considered.
Costs incurred during the maintenance years of ther-
apy were not discounted. The costs associated with the
management of adverse events were not incorporated in
the model, as they were assumed to be the same across
the biologics compared.
Drug acquisition costs were calculated on an annual
basis for both the induction and maintenance years for
each drug. The doses and number of administrations for
each product were taken from the respective European
Medicines Agency summaries of product characteristics
(Table 3). According to expert medical opinion inTable 4 Administration setting (%) for biologic agents
Agent Hospital Pharmacy Dermatologist’s private office
Adalimumab 9 12 2
Etanercept 11 12 4
Infliximab 99 0 1
Ustekinumab 68 3 2
Note: The percentages do not sum up to 100% across all rows because of roundingGreece, for patients receiving ustekinumab, approxi-
mately 7% of patients weighing >100 kg receive 90 mg
ustekinumab rather than the standard dose of 45 mg.
This proportion was deemed to be too small to be incor-
porated in the model.
Prices of the biologics were taken from officially pub-
lished price bulletins from the Ministry of Development
(www.ypan.gr). Tariffs from the largest social health in-
surance fund (www.ika.gr) were used to assess monitor-
ing (outpatient visits to dermatologist), administration
(visits to nurse, day hospital, or dermatologist’s private
office), and inpatient costs.
In order to capture the total health care costs for the
treatment of psoriasis, the type of costs considered in
this analysis incorporated not only drug acquisition costs
but also associated medical resource use costs, including
resource costs for non-responders such as supportive
care, outpatient visits, and hospitalization.
From a health care system perspective, office visits
represent a substantial usage of health care infrastruc-
ture and are therefore an important component of fixed
health care costs. For this reason, dispensing fees, ad-
ministration costs, and office visits are commonly fac-
tored into economic analyses in the economic evaluation
literature. This has been the preferred approach in nu-
merous studies, even though the charges for administra-
tion costs may not necessarily differ between the
therapies being compared (e.g., multivalent vaccines and
infusion cancer therapies, in which office visits and ad-
ministration costs are critical components of the eco-
nomic analysis) [29,30]. This approach has been
endorsed by the “Good Research Practices for Measuring
Drug Costs in Cost Effectiveness Analyses” developed by
the International Society for Pharmacoeconomics and
Outcomes Research [31]. This document indicates that
the administration cost of a medication is an integral
part of the overall cost of treatment and, in fact, eco-
nomic evaluations should go beyond the acquisition cost
of drugs in order to reflect real-life clinical practice.
Sensitivity analysis
In order to assess the impact of uncertainty of various
model inputs on the results of the study, univariate sensi-
tivity analyses were conducted on three variables that con-






Table 5 Annual number of visits to health care





Adalimumab 6 5 2
Etanercept 6 5 2
Infliximab 5 2 0
Ustekinumab 6 4 1
Table 7 Mean annual number of additional visits for
non-responders to biologic agents
Visit Location Mean number of additional visits
Hospital 6
Dermatologist’s private office 6
GP private office 0
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supportive care costs for non-responders; and market
share of ustekinumab. Non-responders’ health care costs
were varied, with the variation attributed to differences in
resource use (i.e., the number of inpatient and outpatient
visits). These costs were allowed to vary by ±10% in one-
way sensitivity analyses, whereas the market share of uste-
kinumab for years 1–5 was allowed to vary by ±3% and
±6% (the latter being equally distributed to or withdrawn
from all other biologic agents).Results
Primary research results
Interviews with dermatologists and the expert panel
validation that followed showed that 8% of patients
with skin disease visiting a dermatologist are diagnosed
with psoriasis. Of patients with psoriasis visiting a
dermatologist, 63% have moderate to severe disease; of
these, 28% are eligible for biologic therapies.
This primary research also showed that there is some
variability in where patients receive their medicine, de-
pending on the agent in question (Table 4).
The number of visits of patients with psoriasis to
health care professionals for monitoring the progress of
their psoriasis, outside the visits for treatment adminis-
tration purposes, is presented in Table 5. For all the bio-
logics, patients more commonly visit hospitals than
dermatologists’ private offices.
The annual number of visits to dermatologists increases
with disease severity (Table 6). Non-responders to biologic
agents have on average 6 additional visits to hospitals and
6 additional visits to dermatologists per year compared
with responders (Table 7).
Finally, the expert panel provided estimates of the
market share of ustekinumab and the other biologicTable 6 Mean annual number of visits to dermatologists,
by severity of disease and work location of the
dermatologist
Work Location Moderate psoriasis Severe psoriasis
Office-based dermatologist 7 8
Hospital-based dermatologist 6 10agents, after the introduction of the former for the treat-
ment of moderate to severe psoriasis (Table 8). Usteki-
numab’s market share is expected to increase over a
5 year time horizon, starting from 9% in year 1 and
reaching 26% in year 5.
Model results
Based on the model results, the inclusion of ustekinu-
mab in the biologic treatment setting for moderate to
severe psoriasis is predicted to lead to total per-patient
savings of €443 and €900 in years 1 and 5 of its intro-
duction, respectively (Figure 1).
These results are mainly driven by the low number of
administrations required with ustekinumab over a 5-year
treatment period (22 for ustekinumab, compared with
272 for etanercept, 131 for adalimumab, and 36 for
infliximab; Table 9). The cost savings for ustekinumab
are also attributable to reduced hospitalization costs for
non-responders and improved efficacy.
Sensitivity analyses
Results of the sensitivity analyses confirmed the robustness
of the model to wide variation in inputs. Variation of non-
responders’ outpatient costs by ±10% led to a minor
change in the net budget impact of ustekinumab. Variation
of non-responders’ hospitalization costs brought greater
changes to ustekinumab’s budget impact, as hospitalization
is an important cost driver of psoriasis. However, ustekinu-
mab remained cost-saving at both ends of the range of
inputs for hospitalization costs in the sensitivity analysis
(Table 10).
In addition, even using the more conservative base-
case market share assumption for ustekinumab (−10%),
the introduction of ustekinumab as a treatment option
for moderate to severe psoriasis is predicted to deliver
substantial annual cost savings per patient, ranging from
€254 in year 1 to €665 in year 5.Table 8 Estimated market share (%) of biologic agents
for the treatment of moderate to severe psoriasis
Agent Base year Year 1 Year 2 Year 3 Year 4 Year 5
Adalimumab 30 27 25 24 23 23
Etanercept 45 42 39 37 36 35
Infliximab 25 22 20 18 17 16























Figure 1 Net budget impact of ustekinumab (annual cost savings per patient in €).
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Moderate to severe psoriasis is a chronic, incurable dis-
ease, with substantial economic consequences for the
health care budget. This is the first study to investigate
the treatment patterns and resource utilization of psoria-
sis in Greece and the economic impact of the introduc-
tion of a new biologic treatment option.
The current study consisted of two parts: field work
with questionnaires to dermatologists to identify re-
source use data; and a budget impact model to estimate
the costs associated with adding ustekinumab to the
current treatment options for psoriasis. The collection of
resource use data through face-to-face interviews withTable 9 Number of administrations for each product
Agent Induction year Maintenance year 5 year total
Adalimumab 27 26 131
Etanercept 64 52 272
Infliximab 8 7 36
Ustekinumab 5 4 22physicians, rather than being derived from clinical trials
or observational studies, could be criticized on the
grounds of subjectivity and be considered a limitation of
this study. However, in order to strengthen the validity
of the data collected, an expert panel consisting of key
opinion leaders was set up to assess the primary results.
The selection of dermatologists to participate in the
primary research was mainly based on the level of ex-
perience they had with psoriatic patients, the rationale
being that physicians with more experience on psoriasis
would be able to provide more robust estimates for the
parameters investigated in the study. As a result, the
estimated eligible patient population entering the model
in year 1 is potentially shifted upwards compared to ac-
tual numbers, leading to a subsequent overestimate in
the budget impact of the related biologic treatments.
However, the results of the present study in terms of
cost differences across treatments, are not affected, as
the eligible population is the same for all treatments and
therefore has a proportionate impact on respective
budgets.
Table 10 Sensitivity analysis of net budget impact of ustekinumab per patient (€)
Year 1 Year 2 Year 3 Year 4 Year 5
Base case −443 −674 −786 −847 −900
Non-responders’ outpatient costs
−10% −443 −673 −785 −846 −899
+10% −444 −674 −786 −848 −901
Non-responders’ hospitalization costs
−10% −417 −647 −759 −820 −873
+10% −470 −700 −812 −874 −927
Ustekinumab share
−5% −340 −559 −671 −732 −785
+5% −547 −789 −901 −962 −1,015
−10% −254 −441 −552 −614 −665
+10% −648 −906 −1,018 −1,080 −1,133
Note: Negative values indicate budget savings.
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ferred treatment option for moderate to severe psoriasis,
followed by adalimumab and infliximab. An interesting
finding is that although etanercept and adalimumab are
administered at home for the majority of patients,
patients more commonly visit hospital-based physicians
than the private offices of dermatologists to monitor
their treatment progress. This may be attributed to the
fact that specialized psoriasis centers are located in some
hospitals.
The results also show that resource utilization and
related costs increase with disease severity, a finding
confirmed by the literature [32]. Moreover, the investiga-
tion of the budget impact of adding ustekinumab as a
treatment option for psoriasis shows that this would lead
to substantial cost savings, even in the first year of its
introduction.
The therapeutic benefits of ustekinumab have been
confirmed in three large Phase 3 trials in patients with
moderate to severe psoriasis [25,26,28]. These studies
found that a significantly higher proportion of patients
receiving ustekinumab compared with placebo or etaner-
cept achieved PASI 75 at 12 weeks. Other efficacy mea-
sures, including the Physician’s Global Assessment at
week 12, also favored ustekinumab [25,26,28]. Moreover,
subcutaneous ustekinumab was generally well tolerated
[24-26,28]. Treatment with ustekinumab has also been
found to result in significantly improved HRQoL
(Dermatology Life Quality Index) [33,34], lowered de-
pression and anxiety rates based on the Hospital Anxiety
and Depression Scale [34], and improved employability
and productivity [35].
A possible shortcoming of the present study is that
hospitalization and outpatient costs may have been
underestimated. Social health insurance fund tariffs,
which have been used in this model, do not reflect actualcosts; actual costs are higher than the amount reim-
bursed by insurance funds.
Another limitation is that indirect costs were not con-
sidered. Indirect costs related to psoriasis include lost
work time (i.e., days missed from work) and reduced
productivity. Indirect costs increase with disease severity
and can be significant [32]. In a UK study, 59.3% of
patients with psoriasis who were still working had lost
an average of 26 days from work in the previous year be-
cause of their psoriasis, and of the 180 patients not
working, 33.9% reported not working because of their
psoriasis [36]. A study in Germany showed that the
mean indirect costs and loss of productivity per patient
with psoriasis were €1,310 per year, accounting for
19.5% of total psoriasis costs [37]. However, clinical trials
of biologics, including ustekinumab, demonstrate that
patients who respond to treatment experience improve-
ments in productivity and reductions in work-day loss.
Therefore, the omission of indirect costs in this analysis
is unlikely to adversely affect the research findings.
An important finding of this study is that, based on
expert opinion, 67.5% of ustekinumab-treated patients
will initially be administered the product in hospital ra-
ther than at home or in their dermatologist’s private
office. This is probably due to physicians’ reservations
regarding a new biologic agent. According to the expert
panel, reinforcement of ustekinumab’s efficacy and safety
data with local dermatologists’ own experience is likely
to lead to patients receiving the drug outside of the hos-
pital setting. The expert panel’s opinion was that similar
treatment patterns as with etanercept and adalimumab
(where 58% and 60% of patients, respectively, perform
administration at home) are expected for ustekinumab
users in the future.
Two Phase 3 studies of ustekinumab have shown that
the drug has a comparable safety profile with self-
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professional [25,26]. A movement toward more frequent
administration at home rather than in the hospital set-
ting could further reduce the direct costs of ustekinu-
mab use.
Overall, the present study investigated, for the first
time in Greece, the treatment patterns and resource
utilization of patients with moderate to severe psoriasis.
These findings may be used to inform the development
of national treatment guidelines in psoriasis and health
policy resource allocation decisions.
Conclusions
Ustekinumab offers a promising alternative to currently
approved biologic agents for psoriasis, with both short-
and long-term economic benefits. Based on the present
model calculation, the introduction of ustekinumab as
an alternative treatment option for moderate to severe
psoriasis in Greece is anticipated to bring substantial
cost savings to the national health care budget.
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